MABVAX THERAPEUTICS HOLDINGS INC Inactive Instrument
Mabvax Therapeutics Holdings Inc Stock Nasdaq
Equities
US55414P5044
Biotechnology & Medical Research
Financials (USD)
| Sales 2016 | 148K | Sales 2017 | - | Capitalization | 14.41M |
|---|---|---|---|---|---|
| Net income 2016 | -17M | Net income 2017 | -19M | EV / Sales 2016 | 147 x |
| Net Debt 2016 | 470K | Net Debt 2017 | 2.48M | EV / Sales 2017 | - |
| P/E ratio 2016 |
-0.93
x | P/E ratio 2017 |
-0.25
x | Employees | - |
| Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 92.02% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 72 | - | |
| Chief Tech/Sci/R&D Officer | 81 | 14-07-07 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 14-07-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | 81 | 14-07-07 |
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform. The Company is focused on the translation into clinical development of products to address the medical needs in the treatment of cancer and pancreatitis. The Company discovered a pipeline of human monoclonal antibody product candidates based on the immune responses generated by patients. The Company's product pipeline includes ImmunoPET Imaging (MVT-2163) and Radioimmunotherapy (MVT-1075). MVT-2163 is an imaging agent for pancreatic cancer. MVT-1075 is a radioimmunotherapy for pancreatic cancer.
| 1st Jan change | Capi. | |
|---|---|---|
| -1.49% | 105B | |
| +3.58% | 97.5B | |
| +1.86% | 22.19B | |
| -16.73% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.40% | 14.52B | |
| +5.59% | 14.09B | |
| +28.97% | 10.99B |
